Olmesartan improves endothelial function in hypertensive patients: Link with extracellular superoxide dismutase

Hypertension Research

Volumn 34, Issue 6, 2011, Pages 686-692

  Takiguchi, Shunichi ^a,b   Ayaori, Makoto ^a   Uto Kondo, Harumi ^a   Iizuka, Maki ^a   Sasaki, Makoto ^a   Komatsu, Tomohiro ^a   Takase, Bonpei ^a   Adachi, Tetsuo ^c   Ohsuzu, Fumitaka ^b   Ikewaki, Katsunori ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Department of Internal Medicine   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ARB; EC SOD; endothelial dysfunction; FMD

Indexed keywords

AMLODIPINE; ANTIOXIDANT; C REACTIVE PROTEIN; LIPID; OLMESARTAN; PROSTAGLANDIN F2 ALPHA; SUPEROXIDE DISMUTASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG DOSE TITRATION; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LIPID ANALYSIS; MALE; MICROALBUMINURIA; OXIDATIVE STRESS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SUPEROXIDE DISMUTASE; TETRAZOLES; VASODILATION;

EID: 79958154807     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.11     Document Type: Article

References (47)

1. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27. (Pubitemid 20209468)
2. Ghiadoni L, Taddei S, Virdis A, Sudano I, Di Legge V, MeolaM, Di Venanzio L, Salvetti A. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998; 32: 25-32. (Pubitemid 28324120)
3. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002; 20: 1671-1674.
4. Schiffrin EL. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 2002; 15: 115S-122S. (Pubitemid 35155530)
5. Al Khalaf MM, Thalib L, Doi SA. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. Am J Cardiovasc Drugs 2009; 9: 29-43.
6. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, Drexler H. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799-805. (Pubitemid 32163876)
7. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286. (Pubitemid 36706078)
8. Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, Miho N, Ishida T, Ishida M, Yoshizumi M, Kambe M. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res 2005; 28: 889-894. (Pubitemid 43173958)
9. Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C. Essential hypertension: is there a role for inflammatory mechanisms? Cardiol Rev 2009; 17: 216-221.
10. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008; 5: 338-349. (Pubitemid 351761708)
11. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992; 90: 2548-2554. (Pubitemid 23010077)
12. Gilligan DM, Sack MN, Guetta V, Casino PR, Quyyumi AA, Rader DJ, Panza JA, Cannon III RO. Effect of antioxidant vitamins on low density lipoprotein oxidation andimpaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994; 24: 1611-1617. (Pubitemid 24369183)
13. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 2004; 110: 821-825. (Pubitemid 39096010)
14. Imai Y, Otsuka K, Kawano Y, Shimada K, Hayashi H, Tochikubo O, Miyakawa M, Fukiyama K. Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771-782. (Pubitemid 37406944)
15. Shirasaki O, Terada H, Niwano K, Nakanishi T, Kanai M, Miyawaki Y, Souma T, Tanaka T, Kusunoki T. The Japan home-health apparatus industrial association: investigation of home-use electronic sphygmomanometers. Blood Press Monit 2001; 6: 303-307. (Pubitemid 34194884)
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002; 39: 257-265. (Pubitemid 34084631)
17. Uehata A, Lieberman EH, Gerhard MD, Anderson TJ, Ganz P, Polak JF, Creager MA, Yeung AC. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med 1997; 2: 87-92. (Pubitemid 27428396)
18. Adachi T, Ohta H, Yamada H, Futenma A, Kato K, Hirano K. Quantitative analysis of extracellular-superoxide dismutase in serum and urine by ELISA with monoclonal antibody. Clin Chim Acta 1992; 212: 89-102.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. (Pubitemid 15018832)
20. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 1993; 84: 407-412. (Pubitemid 23113948)
21. Morrow JD, Harris TM, Roberts II LJ. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem 1990; 184: 1-10. (Pubitemid 20029736)
22. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
23. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425-432. (Pubitemid 36722208)
24. Kimura Y, Matsumoto M, Den YB, Iwai K, Munehira J, Hattori H, Hoshino T, Yamada K, Kawanishi K, Tsuchiya H. Impaired endothelial function in hypertensive elderly patients evaluated by high resolution ultrasonography. Can J Cardiol 1999; 15: 563-568. (Pubitemid 29265488)
25. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107. (Pubitemid 39319009)
26. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, Shin EK. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010; 140: 73-81.
27. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 2006; 24: S39-S43. (Pubitemid 44336822)
28. De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. Eur J Pharmacol 2005; 516: 253-259. (Pubitemid 40922746)
29. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-2183.
30. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
31. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, Ellahham S, Quyyumi AA. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-2354. (Pubitemid 30329123)
32. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-mas axis and oxidative stress in cardiovascular disease. Hypertens Res 2011; 34: 154-160.
33. Igase M, Kohara K, Nagai T, Miki T, Ferrario CM. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type .1. receptor blockade. Hypertens Res 2008; 31: 553-559. (Pubitemid 351597510)
34. Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995; 15: 2032-2036.
35. Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H, Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000; 101: 2264-2270. (Pubitemid 30317128)
36. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007; 50: 1144-1149. (Pubitemid 47375012)
37. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
38. Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med 2006; 119: S40-S47.
39. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl JMed 2001; 345: 861-869.
40. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study. Kidney Int Suppl 2004; 92: S42-S44. (Pubitemid 43361429)
41. Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006; 47 (Suppl 2): S151-S162; discussion S172-S176. (Pubitemid 44620205)
42. Ikeda H, Hamamoto Y, Honjo S, Nabe K, Wada Y, Koshiyama H. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83: 117-118.
43. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008; 103: 398-406.
44. Qamirani E, Ren Y, Kuo L, Hein TW. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2005; 25: 995-1001. (Pubitemid 40627845)
45. Sugihara M, Miura S, Takamiya Y, Kiya Y, Arimura T, Iwata A, Kawamura A, Nishikawa H, Uehara Y, Saku K. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32: 625-630.
46. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, Fogari E, D'Angelo A, Cicero AF. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010; 33: 790-795.
47. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose T, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13. (Pubitemid 351325609)